After disappointing sales, Novartis trades in the Sandoz US dermatology business and generic oral solids portfolio to Aurobindo Pharma, in a deal worth nearly $1 billion. According to Novartis’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback